The efficacy of azathioprine in relapsing-remitting multiple sclerosis

Neurology

Volumn 41, Issue 1, 1991, Pages 20-25

  Goodkin, D E ^a   Bailly, R C ^b   Teetzen, M L ^c   Hertsgaard, D ^d   Beatty, W W ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Fargo Clinic   (United States)

^c Grand Forks Clinic   (United States)

^d 112 D H Research Statistical Consultants ^*  (United States)

^e NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AZATHIOPRINE; DISABILITY EVALUATION; HUMAN; MIDDLE AGE; MULTIPLE SCLEROSIS; RECURRENCE; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS;

EID: 0026098973     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.41.1.20     Document Type: Article

References (19)

1. Hafler DA, Weiner HL. MS: a CNS and systemic autoimmune disease. Immunol Today 1989;10:104-107.
2. Ellison GW, Myers LW. A review of systemic nonspecific immunosuppressive treatment of multiple sclerosis. Neurology 1978;28(suppl):132-139.
3. Hughes RAC. Immunological treatment of multiple sclerosis. I. J Neurol 1983;230:73-80.
4. Mertin J. Drug treatment of patients with multiple sclerosis. In: Koetsier JC, ed. Handbook of clinical neurology, vol 47, no. 3. New York: Elsevier, 1985:187-212.
5. Rosen JA. Prolonged azathioprine treatment of non-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1979;42:338-344.
6. Patzold U, Pocklington P. Azathioprine in MS: a three-year controlled study of its effectiveness. J Neurol 1980;223:97-119.
7. Swinburn WR, Liversedge LA. Azathioprine and multiple sclerosis. J Neurol Neurosurg Psychiatry 1973;36:16-19.
8. Mertin J, Rudge P, Kremer M, et al. Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report. Lancet 1982;2:351-354.
9. Zeeberg IA, Heltberg JH, Kristensen NE, et al. Azathioprine (Imuran) in the treatment of progressive multiple sclerosis. In: Hommes OR, Mertin J, Tourtellotte WW, eds. Immunotherapies in multiple sclerosis. Sutton, UK: Stuart Phillips, 1986:295-300.
10. Ellison GW, Myers LW, Mickey MR, et al. A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology 1989;39:1018-1026.
11. British and Dutch multiple sclerosis azathioprine trial group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988;2:179-183.
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
13. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
14. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983;308:173-180.
15. Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole-peg-tests. Arch Phys Med Rehabil 1988;69:850-854.
16. Ellison GW, Myers LW, Mickey RM, et al. Clinical experience with azathioprine: the pros. Neurology 1988;38(suppl 2):20-23.
17. Goodkin D, Hertsgaard D, Rudick R. Exacerbation rates and adherence to disease type in a prospectively followed MS population: implications for clinical trials. Arch Neurol 1989;46:1107-1112.
18. Lhermitte F, Marteau R, Roullet R. Not so benign long-term immunosuppression in multiple sclerosis. Lancet 1984;1:276-277.
19. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985;78(suppl 1A):44-49.